Abstract
Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Current Signal Transduction Therapy
Title: New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Volume: 6 Issue: 2
Author(s): Fabio Farinati, Nora Cazzagon, Anna Giacomin and Anna
Affiliation:
Keywords: Hepatocellular carcinoma, kinase inhibitors, molecular therapy, signal pathways, treatment, Sorafenib, Organ- Specific Drug, Bevacizumab, Vatalanib, Sunitinb, Cediranib, SU6668, Dovitinib, Brivanib, ABT 869, Cetuximab, Gefitinib, Erlotinib, Lapatinib, ABT-100, Rapamycin, Everolimus, VEGF, TGF, EGF, IGFs, FGF, HGF
Abstract: Despite the advancements in diagnosis and therapy for hepatocellular carcinoma (HCC) that currently permit to treat with tailored strategies the disease in early stages, for intermediate and advanced stages the therapeutic options are far from optimal. In recent years, new targets have been searched by exploring the molecular pathways involved in hepatocarcinogenesis, leading to multiple trials on new agents interfering in these mechanisms.
In this article we revised the principal agents that raised major interest, from the one already established as gold standard for advanced HCC (sorafenib) to the new molecules still in preclinical or early clinical studies. The extensive investigation on the field will identify the best agents and the subsets of patients that will benefit most from their application.
Export Options
About this article
Cite this article as:
Farinati Fabio, Cazzagon Nora, Giacomin Anna and Anna , New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795660034
DOI https://dx.doi.org/10.2174/157436211795660034 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Gadoxetic Acid-enhanced MRI to Predict the Development of Postoperative Pancreatic Fistulas by Estimating the Degree of Pancreatic Fibrosis
Current Medical Imaging Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Endogenous Enzyme-responsive Nanoplatforms for Anti-tumor Therapy
Current Drug Targets An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Polo-Like Kinases (Plks) are Prognostic Markers for Gynecologic Malignancies
Current Women`s Health Reviews Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Meet the Editorial Board:
Recent Patents on Anti-Cancer Drug Discovery Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Carcinogenesis and Diabetic Wound Healing: Evidences of Parallelism
Current Diabetes Reviews The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Quantificational Methylation Analysis of APC and AXIN2 in HBV-related Hepatocellular Carcinoma
Current Cancer Therapy Reviews Stress Signaling from Irradiated to Non-Irradiated Cells
Current Cancer Drug Targets Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents
Infectious Disorders - Drug Targets